Three major outbreaks of the coronavirus, a zoonotic virus known to cause respiratory
disease, have been reported since 2002, including SARS-CoV, MERS-CoV and the most …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …

Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been
intensely investigated for clinical applications within the last decades. However, the majority …

The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

This survey explores how Deep Learning has battled the COVID-19 pandemic and provides
directions for future research on COVID-19. We cover Deep Learning applications in Natural …

COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes
only mild symptoms in the majority of the cases, while immunologic complications such as …